secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0000950170-24-037643
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara posts Q4 loss $0.56/sh; tab-cel BLA submission on track for Q2 2024
-------------------------------------------------------------------------

- Q4 net loss $60.5M ($0.56/diluted share); FY 2023 net loss $276.1M ($2.61/diluted share).
- Cash, cash equivalents and short-term investments $51.7M at Dec 31, 2023; pro-forma ~$104M after Q1 2024 proceeds.
- Tab-cel BLA submission on track for Q2 2024; $20M regulatory milestone expected in April 2024.
- ATA3219 lupus nephritis Phase 1 to start H2 2024, initial data H1 2025; NHL study enrolling with data Q4 2024.
- Two workforce reductions: ~30% in Nov 2023 and further ~25% in Jan 2024; headcount now ~170.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017024037643/0000950170-24-037643-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017024037643/atra-20240328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-037643

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer